Sartar Therapeutics Ltd.
Developing a new precision medicine product to treat sarcomas.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 -25.6x EV/EBITDA | round | |
| investor | €0.0 Valuation: €0.0 -335.0x EV/EBITDA | round | |
| investor | €0.0 | round | |
N/A | - | ||
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Sartar Therapeutics Ltd. operates as a clinical-stage biotechnology firm focused on developing treatments for soft tissue sarcomas. The company was established in 2021 by Professor Jonathan Fletcher, a distinguished figure from Brigham and Women's Hospital and Harvard Medical School. His extensive background in sarcoma pathology and genetics provides a strong scientific foundation for the company's research and development activities. Sartar Therapeutics is built upon years of foundational research conducted at Professor Fletcher's laboratory, which has been instrumental in identifying therapeutic targets for various cancers.
The company's primary objective is to address the significant unmet medical need in the treatment of soft tissue sarcomas, a diverse and challenging group of cancers. Sartar Therapeutics is advancing a pipeline of proprietary drug candidates. The business model centers on progressing these candidates through preclinical and clinical trials, with the ultimate goal of commercialization or partnership with larger pharmaceutical companies. By concentrating on personalized medicine, the firm aims to provide effective therapeutic solutions for patients who currently lack specific treatment options or have exhausted existing therapies.
Keywords: soft tissue sarcoma, oncology, biotechnology, clinical-stage, personalized medicine, cancer therapy, drug development, rare diseases, targeted therapy, precision oncology